Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Recovery, dyspnea -125% Improvement Relative Risk Recovery, ague -433% Recovery, weakness 73% Recovery, muscular pain 40% Recovery, headache 38% Recovery, sore throat -71% Recovery, sputum cough 12% Recovery, dry cough 0% c19early.org/t Askari et al. IRCT20121216011763N46 Curcumin RCT EARLY Is early treatment with curcumin beneficial for COVID-19? Double-blind RCT 26 patients in Iran (November 2020 - April 2021) Worse recovery with curcumin (not stat. sig., p=0.58) Askari et al., Trials, doi:10.1186/s13063-022-06375-w Favors curcumin Favors control
The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial
Askari et al., The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and.., Trials, doi:10.1186/s13063-022-06375-w, IRCT20121216011763N46
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small RCT 46 outpatients in Iran, 23 treated with curcimin-piperine, showing no significant differences in recovery. 1000mg curcumin and 10mg piperine/day for 14 days.
risk of no recovery, 125.0% higher, RR 2.25, p = 0.58, treatment 3 of 8 (37.5%), control 1 of 6 (16.7%), dyspnea.
risk of no recovery, 433.3% higher, RR 5.33, p = 0.19, treatment 2 of 6 (33.3%), control 0 of 7 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), ague.
risk of no recovery, 72.9% lower, RR 0.27, p = 0.04, treatment 2 of 12 (16.7%), control 8 of 13 (61.5%), NNT 2.2, weakness.
risk of no recovery, 40.0% lower, RR 0.60, p = 0.42, treatment 3 of 10 (30.0%), control 7 of 14 (50.0%), NNT 5.0, muscular pain.
risk of no recovery, 38.5% lower, RR 0.62, p = 0.65, treatment 4 of 13 (30.8%), control 4 of 8 (50.0%), NNT 5.2, headache.
risk of no recovery, 71.4% higher, RR 1.71, p = 1.00, treatment 2 of 7 (28.6%), control 1 of 6 (16.7%), sore throat.
risk of no recovery, 12.5% lower, RR 0.88, p = 1.00, treatment 1 of 8 (12.5%), control 1 of 7 (14.3%), NNT 56, sputum cough.
risk of no recovery, no change, RR 1.00, p = 1.00, treatment 3 of 13 (23.1%), control 3 of 13 (23.1%), dry cough.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Askari et al., 6 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 11 authors, study period November 2020 - April 2021, trial IRCT20121216011763N46.
Contact: baghrerniya@nutr.mui.ac.ir (corresponding author).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Abstract: (2022) 23:472 Askari et al. Trials https://doi.org/10.1186/s13063-022-06375-w Open Access RESEARCH The efficacy of curcumin‑piperine co‑supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID‑19 outpatients: a randomized double‑blind, placebo‑controlled trial Gholamreza Askari1,2,3, Amirhossein Sahebkar4,5,6, Davood Soleimani7, Atena Mahdavi3, Sahar Rafiee3, Muhammed Majeed8, Farzin Khorvash9, Bijan Iraj10, Mahshid Elyasi3, Mohammad Hossein Rouhani1 and Mohammad Bagherniya1,2,3*    Abstract Background: COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19. Methods: Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days. Results: Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). Conclusion: The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. Trial registration: Iranian Registry of Clinical Trials IRCT2​01212​16011​763N46. 2020-10-31 Keywords: COVID-19, Curcumin, Piperine, Clinical trial, Clinical symptoms *Correspondence: baghrerniya@nutr.mui.ac.ir 1 Food Security Research Center, Isfahan University of Medical Sciences, PO Box: 00983137922110, Isfahan, Iran Full list of author information is available at the end of the article
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit